Quetiapine-induced neutropenia in a bipolar patient with hepatocellular carcinoma

Han Ching Tang, Kuo Hsuan Chung

研究成果: 雜誌貢獻文章同行評審

7 引文 斯高帕斯(Scopus)


Objective: Quetiapine is a dibenzothiazepine derivative, similar to clozapine, which has the highest risk of causing blood dyscrasias, especially neutropenia. There are some case reports about this side effect of quetiapine, but possible risk factors are seldom discussed and identified. A case of a patient with hepatocellular carcinoma that developed neutropenia after treatment with quetiapine is described here. Case Report: A 62-year-old Taiwanese widow with bipolar disorder was diagnosed with hepatocellular carcinoma at age 60. She developed leucopenia after being treated with quetiapine. After quetiapine was discontinued, her white blood cell count returned to normal. Conclusions: Although neutropenia is not a common side effect of quetiapine, physicians should be cautious about its presentation and associated risk factors. Hepatic dysfunction may be one of the possible risk factors, and concomitant fever may be a diagnostic marker for adverse reaction to quetiapine.

頁(從 - 到)255-261
期刊International Journal of Psychiatry in Medicine
出版狀態已發佈 - 1月 1 2014

ASJC Scopus subject areas

  • 精神病學和心理健康


深入研究「Quetiapine-induced neutropenia in a bipolar patient with hepatocellular carcinoma」主題。共同形成了獨特的指紋。